Wegovy maintenance dose 1mg: where you are in the titration journey

Step one: understanding the five-stage UK titration schedule

Wegovy (semaglutide) is prescribed in the UK as a once-weekly subcutaneous injection, and its dose is not fixed from the start. The licensed schedule begins at 0.25mg, a level that exists purely to help your system adjust, the clinical aim at that stage is tolerability, not weight loss. After roughly four weeks your prescriber moves you to 0.5mg, and after another four weeks to 1mg. That brings you to week eight or so of treatment.

At 1mg you are at the midpoint of the ladder, with 1.7mg and then 2.4mg still ahead. The full Wegovy dose sequence is covered separately, but the key practical point here is that 1mg is a transitional step, not a destination. The NHS semaglutide page describes the titration schedule and explains why gradual increases matter for tolerability.

Your prescriber controls the pace. If side effects at 1mg are significant, they may hold you at that level for longer than four weeks, that is clinically appropriate and common. Moving up before your body is ready does not accelerate results; it usually just amplifies nausea.

Step two: what changes (and what doesn't) at the 1mg stage

One question our prescribers hear regularly: does weight loss actually start at 1mg, or only once you reach maintenance? The honest answer is that meaningful appetite suppression can begin to show at the mid-tier doses, though the full therapeutic effect of Wegovy builds across the whole schedule, and whether you continue to lose weight on the maintenance dose of Wegovy is a question worth exploring as you progress. The STEP 1 trial, published in the New England Journal of Medicine, showed an average weight reduction of around 15% over 68 weeks at 2.4mg, that figure reflects the complete titration journey, not any single dose in isolation.

At 1mg, the GLP-1 mechanism is active: semaglutide slows gastric emptying, signals fullness earlier, and reduces appetite signals in the brain. You may notice smaller portions feeling satisfying, or less interest in eating between meals. Some people notice this clearly; others find the effect more modest until doses increase. Both are normal.

A simple habit worth building at this stage: before each weekly injection, note your injection site in the app or a notebook. Rotating between the abdomen, thigh and upper arm reduces local skin reactions, a small discipline that pays off across months of treatment, and pairing this routine with a clear sense of your Wegovy maintenance plan helps you stay focused on the longer journey ahead. You can check your last site in under a minute before picking up the pen.

Step three: moving toward the 2.4mg maintenance dose

The 2.4mg weekly dose is where Wegovy's licensed maintenance sits for most adults. Getting there from 1mg means one more intermediate step at 1.7mg, each held for roughly four weeks, so you are typically looking at eight to twelve weeks from 1mg to sustained maintenance, longer if your prescriber decides a slower pace suits you better.

NICE's appraisal of semaglutide (TA875) notes that continuing treatment should be reviewed if weight loss is less than 5% after six months at the maintenance dose. That review happens at the maintenance stage, not at 1mg, so reaching and sustaining 2.4mg is the clinical threshold against which your progress is formally assessed.

For a fuller picture of what to expect once you get there, the question of whether Wegovy has a true maintenance dose is worth reading alongside this page. And if you're thinking about what weight management looks like after a full course, our guide to life after completing a Wegovy course covers the options your prescriber will discuss with you in time.

Side effects at 1mg: what to expect and when to act

Gastrointestinal effects are the most reported across the Wegovy schedule, and 1mg is no exception. Nausea, looser stools, constipation, reflux and reduced appetite are all common, they tend to peak in the first week or two after a dose increase and then ease for most people. Eating smaller, lower-fat meals and staying well hydrated helps significantly during these windows.

Most side effects at this stage are uncomfortable rather than dangerous. The ones that warrant prompt medical attention are different in character: severe stomach pain that radiates to the back could indicate pancreatitis and needs urgent assessment. The MHRA issued a Drug Safety Update in January 2026 reinforcing that acute pancreatitis, while uncommon, is a recognised risk with GLP-1 medicines. If you experience gallbladder pain, signs of dehydration from repeated vomiting, or any allergic reaction, contact a clinician without delay.

You can report suspected side effects at any dose to the MHRA's Yellow Card scheme, it takes a few minutes and contributes to post-market safety monitoring for all patients on these medicines.

If you're weighing up whether your current treatment is the right fit, or you'd like a prescriber to review your progress, check your eligibility for a free consultation with our clinical team.